SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-233500
Filing Date
2023-09-12
Accepted
2023-09-12 16:31:01
Documents
13
Period of Report
2023-09-08
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d638217d8k.htm   iXBRL 8-K 24897
5 GRAPHIC g638217g27b46.jpg GRAPHIC 6536
  Complete submission text file 0001193125-23-233500.txt   165400

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20230908.xsd EX-101.SCH 2890
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20230908_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20230908_pre.xml EX-101.PRE 11288
7 EXTRACTED XBRL INSTANCE DOCUMENT d638217d8k_htm.xml XML 3396
Mailing Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453
Business Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

IRS No.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 231250488
SIC: 8071 Services-Medical Laboratories